Zoetis Inc. (NYSE:ZTS) Position Increased by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its position in Zoetis Inc. (NYSE:ZTS) by 8.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,561,910 shares of the company’s stock after acquiring an additional 433,429 shares during the period. Bank of New York Mellon Corp’s holdings in Zoetis were worth $906,202,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in ZTS. Atlantic Edge Private Wealth Management LLC raised its stake in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares during the period. Darwin Wealth Management LLC purchased a new position in shares of Zoetis during the third quarter valued at $31,000. First Personal Financial Services acquired a new position in Zoetis during the third quarter valued at $33,000. Capital Performance Advisors LLP acquired a new position in Zoetis during the third quarter valued at $33,000. Finally, Dunhill Financial LLC lifted its stake in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ZTS shares. Piper Sandler dropped their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Morgan Stanley cut their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. UBS Group initiated coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Leerink Partners initiated coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $215.40.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Zoetis Price Performance

NYSE ZTS opened at $165.51 on Tuesday. The firm has a market cap of $74.12 billion, a P/E ratio of 30.26, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. The stock’s 50-day moving average is $166.30 and its two-hundred day moving average is $177.78. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.21%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is currently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.